sar425899 sanofi glp-1 glucagon dual agonist Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity How glucagon-like peptide 1 receptor

This confirmed what obesity researchers have argued for years: obesity is a chronic condition that requires ongoing treatment, just like hypertension or diabetes

GLP-1 RAs, synthetic analogues of endogenous GLP-1, stimulate insulin secretion while inhibiting glucagon release, with additional benefits in gastric emptying and appetite suppression [8, 9]

GLP-1 therapies mark more than a scientific breakthrough

So its been going on for a while

Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat)

Individual response to GLP-1 medications varies